Table 3.
Multivariate analysis of the association between HCMV seropositivity and ESS progression during RA, study of ESPOIR cohort
| Erosion Sharp score (baseline–1 year) score Δ > 1 | Odds ratio | Standard error | z | P > lzl | [95% conf. interval] | |
|---|---|---|---|---|---|---|
| Erosion Sharp score at baseline | 5.3180 | 1.9356 | 4.59 | 0.000 | 2.6057 | 10.854 |
| ACPA+ | 5.1915 | 1.7635 | 4.85 | 0.000 | 2.6677 | 10.103 |
| HCMV | 0.5255 | 0.1505 | − 2.25 | 0.025 | 0.2998 | 0.9213 |
| Cumulated dose of glucocorticoids | 0.9997 | 0.0001 | − 2.29 | 0.022 | 0.9995 | 1 |
| Use of csDMARDs | 1.7987 | 1.0696 | 0.99 | 0.324 | 0.5608 | 5.7694 |
| Use of bDMARDs | 1.3298 | 0.9829 | 0.39 | 0.700 | 0.3123 | 5.6619 |